← Back


Leading global specialty pharmaceutical company manufacturing generic and over the counter (OTC) products.

From the start of its involvement in 1999 when the original Bulgarian company had revenues of $100m, Novator took the long view, guiding and advising the business through multiple mergers and acquisitions and a privatisation building the revenue to $15bn.

Sold to Watson in 2012. Novator exited fully in 2016.